21:51:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-08 Kvartalsrapport 2024-Q2
2024-05-13 Ordinarie utdelning OPTOMED 0.00 EUR
2024-05-10 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-03 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-05-11 Ordinarie utdelning OPTOMED 0.00 EUR
2023-05-10 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-09-06 Extra Bolagsstämma 2022
2022-08-04 Kvartalsrapport 2022-Q2
2022-05-11 Ordinarie utdelning OPTOMED 0.00 EUR
2022-05-10 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning OPTOMED 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning OPTOMED 0.00 EUR
2020-06-11 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Optomed är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av specialiserade ögonkameror. Utveckling sker av både hård- och mjukvara som vidaresäljs under olika varumärken. Verksamhet innehas på global nivå, med störst närvaro inom den nordiska marknaden. Kunderna består av forskningsinstitut samt sjukhus. Huvudkontoret ligger i Oulu.
2024-01-10 08:00:00

Optomed PlcStock Exchange Release10 January 2024 at 9:00, Helsinki

Proposal of Optomed's Nomination Board

Optomed's Nomination Board proposes that both the composition and the remuneration of the Optomed Board remains as-is. The complete proposal is as follows:

Number of Board members

The Nomination Board proposes, that the number of members of the Board of Directors for the term expiring at the end of the Annual General Meeting 2025 is six.

Composition of the Board of Directors

The Nomination Board proposes to the Annual General Meeting that all the current Board members, Catherine Calarco, Ty Lee, Seppo Mäkinen, Petri Salonen, Reijo Tauriainen and Anna Tenstam are re-elected as Board members.

Proposal for the remuneration of the Board of Directors

The Nomination Board proposes to the Annual General Meeting that the annual remuneration payable to the members of the Board of Directors to be elected at the Annual General Meeting for the term until the end of the Annual General Meeting in 2024 remains unchanged as follows:
  • EUR 36,000 for the Chairman of the Board; and
  • EUR 18,000 for each Board member

In addition, the Nomination Board proposes that a meeting fee in the amount of EUR 300 is paid to the committee chairmen and EUR 200 to committee members for each committee meeting. The Nomination Board proposes that 40 % of the Board remuneration is paid in Optomed shares and 60 % in cash. The remuneration will be paid once a year in August, after Optomed's H1 report has been announced.

Nomination Board

Optomed's Nomination Board consists of the following individuals:
  • Vesa Vanha-Honko, appointed by OP funds
  • Markus Lindqvist, appointed by Aktia funds
  • Keith Bonnici, appointed by Finnish Industry Investment Ltd

Petri Salonen (chairman of Optomed's Board of Directors) serves as the Nomination Board's expert member and Vesa Vanha-Honko acts as the chairman of the Nomination Board.

Optomed Plc

Further enquiries

Vesa Vanha-Honko, Chairman of the Nomination Board, vesa@vesasco.fi

Sakari Knuutti, secretary of the Nomination Board, Optomed Plc, sakari.knuutti@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.